Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, parents, or legal guardian willing and able to sign informed consent~* Male and female subjects aged ≤18 years of age (females of child-bearing potential willing to practice an acceptable form of birth control)~* Patients undergoing cardiopulmonary bypass for repair of a large unrestrictive ventricular septal defect, an ostium primum/secundum atrial septal defect, or a partial or complete atrioventricular septal defect~* Pre-operative echocardiogram confirming cardiovascular anatomy and defect to be repaired~Exclusion Criteria:~* Evidence of pulmonary artery or vein abnormalities that will not be addressed surgically. Specific abnormalities excluded include:~  * significant pulmonary artery narrowing not amenable to surgical correction~ * previous pulmonary artery stent placement~ * significant left sided AV valve regurgitation not amenable to surgical correction~ * pulmonary venous return abnormalities not amenable to surgical correction~ * pulmonary vein stenosis not amenable to surgical correction~* Preoperative requirement for mechanical ventilation or IV inotrope support~* Presence of fixed or idiopathic pulmonary hypertension (i.e. Eisenmenger's Syndrome) prior to surgical repair~* Pre-operative use of medications to treat pulmonary hypertension~* Pregnancy; Sexually active females of child-bearing potential must be willing to practice an acceptable method of birth control for the duration of study participation (e.g. oral contraceptive, hormonal implant, intra-uterine device)~* Participation in another clinical trial within 30 days of Screening or while participating in the current study, including the 28 days of follow-up post study drug administration.~* Any condition which, in the opinion of the investigator, might interfere with the study objectives

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Patients will receive:~1. an L-citrulline bolus of 150 mg/kg at the initiation of cardiopulmonary bypass~2. the addition L-citrulline to maintain a steady state target concentration of approximately 100 μmol/L of L-citrulline during cardiopulmonary bypass~3. an L-citrulline bolus of 10 mg/kg 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 μmol/L.~Infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first.
- Placebo (Type: PLACEBO_COMPARATOR): Plasmalyte A administered to the same schedule as the active treatment arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).